Create Your Blog
  1. Home
  2. The Biopharmaceutical Contract Manufacturing Market Is Estimated To Be Worth USD 13.9 Billion In 2030, Predicts Roots Analysis

The Biopharmaceutical Contract Manufacturing Market Is Estimated To Be Worth USD 13.9 Billion In 2030, Predicts Roots Analysis

>

The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis

Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

 

Roots Analysis is pleased to announce the publication of its recent study, titled,  “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.” 

 

The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
  • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
  • A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
  • An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
  • An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
  • An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
  • A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
  • Commonly Outsourced Business Operations
  • Active Pharmaceutical Ingredients (API)
  • Finished Dosage Formulations (FDF)
  • Types of Expression System
  • Mammalian
  • Microbial
  • Others
  • Company Size
  • Small
  • Mid-Sized
  • Large and Very Large
  • Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
  • Key Geographical Region 
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World 

 

The report also features detailed transcripts of discussions held with the following experts:

  • Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
  • Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
  • Christian Bailly, Director of CDMO, Pierre Fabre
  • Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
  • Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
  • Kevin Daley, Director Pharmaceuticals, Novasep
  • Mark Wright, Site Head, Grangemouth, Piramal Healthcare
  • Nicolas Grandchamp, R&D Leader, GEG Tech
  • Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
  • Sebastian Schuck, Head of Business Development, Wacker Biotech
  • Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
  • Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
  • Tim Oldham, Chief Executive Officer, Cell Therapies

 

Key companies covered in the report

  • 3P Biopharmaceuticals
  • Abzena
  • Albany Molecular Research
  • BioVectra
  • BioXcellence (Boehringer Ingelheim)
  • Celonic
  • Charles River Laboratories
  • ChemPartner
  • Cobra Biologics
  • CordenPharma
  • Cytovance Biologics
  • GE Healthcare
  • Goodwin Biotechnology
  • Grand River Aseptic Manufacturing
  • IDT Biologika
  • KBI BioPharma
  • Kemwell Biopharma
  • LFB Biomanufacturing
  • Meridian Life Science
  • Patheon
  • Pfizer CentreOne
  • PX'Therapeutics
  • Samsung BioLogics
  • Sanofi, CEPiA
  • Thermo Fisher Scientific
  • Vetter Pharma International

 

For more information please click on the following link:

Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030

 

Other Recent Offerings

  1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
  2. Antibody Contract Manufacturing Market, 2020-2030
  3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
  4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

Share:

Keywords: roots analysis,wellness and fitness,information services,market research,research,medical devices,pharma,healthcare,pharmaceutical,active pharmaceutical ingredient,pharmaceutical product development inc

Comments

FREE BLOG/SBM SITES
Categories

Other related blogs

The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predicts Roots Analysis

By : Roots Analysis

  With multiple approved products, the field of gene therapies has gained substantial momentum..

The gene therapy market is projected to grow at an annualized rate of 45%, till 2030

By : Roots Analysis

Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering k..

The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030

By : Roots Analysis

Recent advances in information technology and biomedical science have enabled the development of a n..

The global digital therapeutics market is projected to be worth over USD 8.8 billion by 2030, predicts Roots Analysis

By : Roots Analysis

Roots Analysis is pleased to announce the publication of its recent study titled, “Digital Hea..